Compare PENN & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENN | HROW |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | PENN | HROW |
|---|---|---|
| Price | $11.85 | $47.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $20.50 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 4.4M | 513.2K |
| Earning Date | 02-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,823,800,000.00 | $250,042,000.00 |
| Revenue This Year | $7.19 | $38.86 |
| Revenue Next Year | $3.11 | $42.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.24 | ★ 47.83 |
| 52 Week Low | $11.66 | $20.85 |
| 52 Week High | $23.08 | $54.85 |
| Indicator | PENN | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 53.97 |
| Support Level | $12.19 | $46.21 |
| Resistance Level | $14.00 | $50.16 |
| Average True Range (ATR) | 0.70 | 2.19 |
| MACD | -0.06 | 0.36 |
| Stochastic Oscillator | 7.85 | 74.14 |
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.